Recruiting
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.
2025-525030-57-00· Phase 3· AstraZeneca AB· Source
Recruiting
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
NCT07775924· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07465289· Phase 3· UCB Biopharma SRL· Source
Recruiting
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
NCT07711002· Phase 3· AstraZeneca· Source
Recruiting
A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.
2025-524488-18-00· Phase 2· Astellas Pharma Global Development Inc.· Source
Recruiting
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
NCT07673627· Phase 2· argenx· Source
Recruiting
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
NCT07647510· Phase 3· Dianthus Therapeutics· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07463521· Phase 3· UCB Biopharma SRL· Source
Active, not recruiting
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
NCT07501702· Phase 2· Vertex Pharmaceuticals Incorporated· Source
Recruiting
Confirmatory Clinical Study in Active Ulcerative Colitis
NCT07296315· Phase 2· MRM Health NV· Source
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· Phase 3· Takeda· Source
Active, not recruiting
A study to investigate the efficacy and safety of TRIV-509 compared with placebo in adults with moderate to severe atopic dermatitis
2025-522113-35-00· Phase 2· Triveni Bio Inc.· Source
Active, not recruiting
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa
2025-520564-17-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336· Phase 2· Genentech, Inc.· Source
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· Phase 3· Pfizer· Source
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004· Phase 3· argenx· Source
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803· Phase 3· AstraZeneca· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901· Phase 2· Inmagene LLC· Source
Recruiting
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
NCT06865651· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
NCT06799247· Phase 3· Cartesian Therapeutics· Source
Recruiting
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
NCT06953869· Phase 3· Vanda Pharmaceuticals· Source
Recruiting
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662· Phase 2· Immunovant Sciences GmbH· Source
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073· Phase 2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496· Phase 3· Takeda· Source
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498· Phase 3· Incyte Corporation· Source
Recruiting
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505· Phase 3· AbbVie· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462· Phase 2· Immunovant Sciences GmbH· Source
Recruiting
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
NCT06636656· Phase 2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
NCT06454188· Phase 4· CARE ARTHRITIS LTD.· Source
Recruiting
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06510374· Phase 3· Ferring Pharmaceuticals· Source
Recruiting
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
NCT06545955· Phase 3· Ferring Pharmaceuticals· Source
Active, not recruiting
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197· Phase 2· AstraZeneca· Source
Active, not recruiting
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT06305767· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
2023-505121-14-00· Phase 3· Janssen - Cilag International· Source
Active, not recruiting
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Plaque Psoriasis Involving Special Areas
2023-505122-34-00· Phase 3· Janssen - Cilag International· Source
Active, not recruiting
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
NCT06021522· Phase 3· Emalex Biosciences Inc.· Source
Enrolling by invitation
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
NCT05707949· Phase 3· AbbVie· Source
Recruiting
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394· Phase 3· AbbVie· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096· Phase 3· Alexion Pharmaceuticals, Inc.· Source
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114· Phase 2/3· Janssen Research & Development, LLC· Source
Recruiting
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398· Phase 3· Pfizer· Source
Recruiting
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
NCT05054140· Phase 2· Immunic AG· Source
Showing 50 of 61.